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Abstract
Background: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease associated with
high morbidity and mortality rates. However, the exact regulatory mechanism of PAH is unknown. Although
coupling factor 6 (CF6) is known to function as a repressor, its role in PAH has not been explored. Here, we
investigated the involvement of endogenous CF6 in the development of PAH.
Methods: PAH was induced with monocrotaline (MCT), as demonstrated by significant increases in pulmonary artery
pressure and vessel wall thickness. The adeno-associated virus (AAV) carrying CF6 short hairpin RNA (shRNA) or control
vector (2×1010 gp) was intratracheally transfected into the lungs of rats 2 weeks before or after MCT injection.
Results: A 2-6-fold increase in CF6 was observed in the lungs and circulation of the MCT-injected rats as confirmed by
qRT-PCR and ELISA. Immunohistochemistry analysis revealed a small quantity of CF6 localized to endothelial cells (ECs)
under physiological conditions spread to surrounding tissues in a paracrine manner in PAH lungs. Notably, CF6 shRNA
effectively inhibited CF6 expression, abolished lung macrophage infiltration, reversed endothelial dysfunction and
vascular remodeling, and ameliorated the severity of pulmonary hypertension and right ventricular dysfunction at
4 weeks both as a pretreatment and rescue intervention. In addition, the circulating and lung levels of 6-keto-PGF1a, a
stable metabolite of prostacyclin, were reversed by CF6 inhibition, suggesting that the effect of CF6 inhibition may
partly be mediated through prostacyclin.
Conclusions: CF6 contributes to the pathogenesis of PAH, probably in association with downregulation of
prostacyclin. The blockage of CF6 might be applied as a novel therapeutic approach for PAH and PA remodeling.
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Background
Pulmonary arterial hypertension (PAH) is a rare but life-
threatening disease characterized by pulmonary vaso-
constriction, endothelial cell proliferation, smooth
muscle cell proliferation, and in situ thrombosis, leading
to progressive pulmonary hypertension and ultimately
causing right ventricular (RV) failure and death [1–3].
Current therapy with prostacyclin analogs, endothelin-1
receptor blockers, and phosphodiesterase inhibitors
improves symptoms and exercise tolerance, but persist-
ent morbidity and mortality indicate that important
pathogenic mechanisms are minimally affected. Thus
more effective therapeutic approaches are urgently
needed [4, 5]. Recently, transfer of the human prostacyc-
lin synthase (PGIS) gene has been shown to ameliorate
monocrotaline (MCT)-induced PAH progression in rats
[6]. However, the molecular networks regulating prosta-
cyclin are largely unknown. Coupling factor 6 (CF6), a
novel essential vascular constrictor, is a known endogen-
ous inhibitor of prostacyclin (PGI2) [7].
CF6 is a subunit of the stalk that joins the membrane
domains, F1 and Fo (F1Fo complex) of mitochondrial ad-
enosine triphosphate (ATP) synthase. CF6 is released
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from the surface of vascular endothelial cells by mechan-
ical forces such as the tumor necrosis factor-alpha
(TNF-α), shear stress, and high glucose levels [8, 9].
More recently, studies showed that plasma membrane-
bound ATP synthase in the vascular endothelial cells
functions as a receptor for CF6 and may play an import-
ant role in affecting vascular function by increasing the
concentration of intracellular proton, acidosis [10]. CF6
suppresses PGI2 synthesis by inhibiting cytosolic
phospholipase A [7] as well as the synthesis of nitric
oxide (NO) generation via upregulation of asymmetric
dimethylarginine [10], thereby profoundly affecting vas-
cular function. Specifically, the CF6 injection consist-
ently induces an elevation in arterial blood pressure [9].
In CF6-overexpressing transgenic mice, endothelial dys-
function increases, and wall thickness and inflammation
are increased in small vessels [11]. These data suggests
that CF6, which directly inhibits PGI2 synthase, may be
present in pulmonary arteries and function as a novel
target in the treatment of PAH.
Therefore, we aimed to determine the involvement of
CF6 in PAH development using MCT-induced PAH rat
models. CF6 RNA interference (RNAi) was used to fur-
ther evaluate the effects of CF6 inhibition on PAH pro-
gression. Here, we have demonstrated for the first time
that CF6 is released into the extracellular space in MCT-
injected rats and that it contributes to PAH develop-
ment. Our findings provide novel insights into the mo-
lecular basis of PAH and present a potential therapeutic
target for this disease.
Methods
Preparation of AAV2-CF6-shRNA
A U6 promoter-driven shRNA expression system was
established in an AAV2 vector. Green fluorescent pro-
tein (GFP) expression was separately controlled by a
CMV promoter as a marker for transduction efficiency.
CF6 shRNA was designed based on the siRNA sequence
(GenBank Acc. NM_053602.2) using an siRNA design
tool (Biomiao, Beijing, China) and was screened accord-
ing to the guidelines reported by Elbashir SM et al. [12].
Four selected siRNA target sequences were inserted be-
tween the KpnI and EcoRI sites in a U6-CMV-EGFP/
AAV vector, and an optimal CF6 target (sequence:
5′-CAGGACTTAAAGGCTCTTAAT-3′) was se-
lected. A recombinant adenovirus carrying an siRNA
sequence targeting the eGFP reporter gene (se-
quence: 5′-CACCGTTCTCCGAACGTGTCACGTCA
AGAGATTACGTGACACGTTCGGAGAATTTTTTG-3′)
was included as a control. Both the adenovirus-CF6-
shRNA and negative control vectors contained the se-
quence encoding GFP. All constructs were verified by DNA
sequencing, all viral vectors were generated by triple-
plasmid cotransfection of human 293 cells, and
recombinant virions were column purified as previously de-
scribed [13]. Next, viral titers were determined using qPCR
[14]. The resulting AAV2-CF6-shRNA titer was determined
to be 2.5 × 1011 vector genomes (vg)/ml, and the AAV2-
GFP titer was 1 × 1012 vg/ml.
Animal models
Sprague–Dawley rats (6–7 weeks old, weighing 200–
250 g, obtained from the Laboratory Animal Center,
Chinese Academy of Science, Beijing) were used in this
experiment. The rats were housed at 20 ± 3 °C under a
12-h light/12-h dark cycle with free access to food and
water. All procedures were carried out according to ap-
proved protocols and guidelines established by the Shan-
dong University Institutional Animal Care and Use
Committee.
CF6 expression study was performed in 2 models of
PAH: I: animals received a single subcutaneous injection
of MCT (Sigma, St. Louis, MO) (60 mg/kg), which is a
pyrrolizidine alkaloid that has been previously reported
to induce PAH at 2 to 3 weeks after injection [15]. The
animals in the sham group received subcutaneous injec-
tion of saline. The 24 survivors of the 40 enrolled rats
(mean survival rate = 60 %) were randomly assigned to
the following 4 groups: 1) the MCT-vehicle-1 week
group (n = 6); 2) MCT-vehicle-2 week group (n = 6); 3)
MCT-vehicle-3 week group (n = 6); and 4) MCT-vehicle-
4 week group (n = 6). II: animals intubated via tracheot-
omy, and ventilated with a small-animal ventilator (HX-
300S, TME, Chengdu, China), with an adjusted rate of
60 breaths/min and a tidal volume set to 1.1–1.3 ml/
100 g body weight, then received left unilateral pneu-
monectomy as described previously [16]. Seven days
after pneumonectomy rats received MCT or saline injec-
tion. As a result, 24 survivors of the 56 enrolled rats
(mean survival rate = 43 %) were randomly assigned to
the 4 groups as reported in I (n = 6 per group).
CF6 knockdown experiment was performed to evaluate
the prevention and reversal effect of CF6 inhibition, the rats
were randomly assigned to the following groups: the sham
group (n = 20), MCT-vehicle group (n = 30), MCT-control
group (n = 60) and MCT-shRNA group (n = 40). The
MCT-control group received intratracheally injection of
AAV-GFP-shRNA, while the MCT-shRNA group received
intratracheally of AAV-shRNA-CF6 (80 μl; 2.5 × 1011 vg/
ml) at 2 weeks prior or 2 weeks after MCT injection [6].
The MCT-control and MCT-shRNA groups were further
divided into two subgroups by virus injection time-point:
i.e. -2w-MCT group (n = 30), 2w-MCT group (n = 30),
−2w-shRNA group (n = 20), and 2w-shRNA group (n = 20).
All animals were sacrificed at 4 weeks after MCT injection.
The rats were monitored daily until they developed pul-
monary hypertension symptoms such as weight loss and
tachypnea until 28 days after MCT administration.
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Hemodynamic, morphologic, and biochemical assessments
were performed.
Echocardiography and hemodynamic measurements
The rats in the experimental groups were anesthetized
by intraperitoneal injection of sodium pentobarbital
(30 mg/kg). The room temperature was maintained at
approximately 25 °C to avoid hypothermia. A Visual
Sonics Vevo 770 echocardiographic machine (Visual
Sonics, Toronto, Canada) equipped with a 14-MHz lin-
ear transducer was used to assess cardiac function. The
measurements were performed in a blinded manner by
an echocardiographic expert. Short- and long-axis B-
dimensional parasternal views of both ventricles at the
level of the papillary muscles were acquired to visualize
the areas of the left ventricle (LV) and the right ventricle
(RV). Cardiac output and stroke volume were obtained
from the B-mode long axis according to Simpson's
method, while the pulmonary artery diameter and RV
wall thickness were obtained in M-mode. Doppler was
applied to the pulmonary artery to obtain the pulmonary
artery acceleration time [17].
Blood pressure was evaluated by the tail-cuff method,
using a non-invasive automatic blood pressure recorder
(BP-98A; Softron, Tokyo, Japan). Each value was the
average of at least three consecutive data [18]. Prior to
sacrifice of the animals, RV systolic pressure (RVSP) was
transduced from the right jugular vein into the vena
cava, into the right atrium and then into the right ven-
tricle using a 1.4 F Millar Mikro-Tip catheter transducer
(Millar Instruments Inc., Houston, TX). The position of
the catheter into the right ventricular was vadilated by
acutely increased pressure wave accompanied by the loss of
resistance, then RVSP was measured with Power Lab moni-
toring equipment (Millar Instruments). Hemodynamic
values were automatically calculated using a LabChart 7.0
physiological data acquisition system (AD Instruments,
Sydney, Australia). The animals were then euthanized be-
fore being sacrificed.
Tissue processing and histology
After completion of the above measurements, cardiac ar-
rest was induced by injection of 2 mmol KCl through
the catheter. Blood from the RV was stored at room
temperature for 1 h and was then centrifuged at
3000 rpm at 4 °C for 15 min. Blood serum was collected
and stored at −80 °C, and the rats were euthanized by
exsanguination. Next, the lungs were weighed, and the
L/BW ratio was calculated. The right lung was removed
and frozen in liquid nitrogen for Western blot analysis.
The left lung was inflated with 0.5 % low-melting agar-
ose at a constant pressure of 25 cm H2O, fixed in 10 %
formalin for 24 h and used for small pulmonary artery
and IHC analyses. Then, the heart was excised and the
weight ratio of the right ventricle to the left ventricle
plus the septum (RV/LV + S) was determined using Ful-
ton’s index [19].
Immunohistochemistry
The left lung lobes were longitudinally cut and proc-
essed as described previously [17] by preparing standard
formalin-fixed, paraffin-embedded tissues for HE or
regular immunohistochemistry staining. Tissue samples
were sectioned at a thickness of 5 μm [20]. Sections
stained with hematoxylin and eosin (HE) were examined
at 400x magnification to determine the severity of PAH
in vessels with diameters of either < 50 or 50 to 100 μm,
including the percentage with medial hyperplasia and
the percentage occluded [21]. Anti-CF6 (1:150, Abcam),
α-SMA (1:500; Abcam), PCNA (1:1000; Millipore) and
anti-CD68 (1:400; Santa Cruz) antibodies were used as
primary antibodies. Subsequently, slides were incubated
with an ABC Elite Kit (Vector Laboratories) and DAB
substrate (Vector Laboratories) and counterstained with
hematoxylin.
Lung samples from 10 patients with NCSCL at the
time of a lobectomy or pneumonectomy for localized
lung cancer in the Department of Thoracic Surgery
(Qianfoshan Hospital of Shandong University) from
2012 to 2016. Human lung specimens was fixed in for-
malin for at least 72 h, and then paraffinembedded and
cut into 5-mm slices for histology processing. Immuno-
histochemistry was performed as described above, except
that the anti-CF6 polyclonal antibody was used at a dilu-
tion of 1:300.
A pathologist blinded to the study reviewed 10 sec-
tions per lung. All images were obtained using an Olym-
pus LCX100 Imaging System and analyzed with ImageJ
software (version 1.38x; National Institutes of Health).
The studies were approved by the Institutional Review
Board of Shandong University.
Western blotting
For immunoblot analyses, RIPA buffer (Beyotime Insti-
tute of Biotechnology, Jiangsu, China) was used to ex-
tract total protein from frozen lung tissues. The quantity
of protein extracted from the tissues was measured using
a BCA protein assay reagent kit (Pierce). An equal
amount of total protein (80 μg of lane) from each sample
was resolved on a 5–8 % SDS-PAGE gel and transferred
onto a polyvinylidene difluoride (PVDF) membrane. The
membranes were blocked with 5 % nonfat dry milk in
PBST containing 0.05 % Tween 20 and incubated over-
night at 4 °C with a CF6 primary antibody (1:1500;
Abcam). The blots were developed using an enhanced
chemiluminescence (ECL) detection kit (Millipore) and
visualized using a FluroChem E Imager (Protein-Simple,
Santa Clara, CA, USA). Measurements to determine the
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relative densities were normalized to that of a standard
protein (GAPDH) (Proteintech, Wuhan, China) using
NIH Image J software.
qRT-PCR
Total RNA was extracted from lung tissues with Trizol re-
agent (Invitrogen). cDNA was synthesized from 2 μg RNA
using a Prime Script RT Reagent Kit (TaKaRa, Dalian,
China) according to the manufacturer's instructions. CF6
mRNA expression was determined using gene-specific
primers and SYBR Green 1 with a Bio-Rad iQ5 Multicolor
Real-Time PCR machine (Bio-Rad Laboratories). For each
sample, both GAPDH and the target gene were amplified
in triplicate in separate tubes. Relative gene expression
was calculated by the 2-ΔΔCT method [22] and normalized








Determination of endothelial dysfunction in the
pulmonary artery
After the rats received MCT for 28 days, the branch of
the pulmonary artery next to the heart was removed,
and the pulmonary arteries from the individual rats were
rapidly separated and placed in cold oxygenated Krebs’
solution composed of the following (mmol/L): 118.3
NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4-
7H2O, 25 NaHCO3 and 11.1 glucose. The tissues were
then oxygenated with carbogen gas at 37.0 ± 0.5 °C. The
right and left pulmonary arteries were carefully dissected
to remove fat and connective tissue and cut into 3 mm-
wide rings. After an equilibration period of 2 h at 1.5 g
resting tension, the preparations were exposed to in-
creasing concentrations of Phe (10−10 to 10−5 mol/L).
After a contraction plateau was reached, the pulmonary
artery rings were exposed to increasing concentrations
of ACh (10−10 to 10−5 mol/L) to determine the vasodila-
tion capacity and endothelial dysfunction.
ELISA
The blood samples obtained from the RV were stored at
room temperature for 1 h and were then centrifuged at
3000 rpm at 4 °C for 15 min. Serum samples were col-
lected and stored at −80 °C. The level of 6-keto PGF1a,
a stable metabolite of prostacyclin, was measured to as-
sess prostacyclin production. The serum 6-keto PGF1a
and CF6 levels were measured using a commercial en-
zyme immunoassay kit (EIA Assay Design, Inc.; Ray
Biotech, Norcross, GA, USA) according to the manufac-
turer's instructions. Rat organs were harvested and ho-
mogenized to measure the 6-keto PGF1a levels in the
tissues. The results were expressed as picograms of 6-
keto-PGF1a per milligram of protein.
Statistics
The data are presented as the mean ± standard deviation
(SD). The unpaired t-test was used to compare values
between two groups. ANOVA was used to compare dif-
ferences between more than two groups, followed by a
Newman–Keuls test. Analyses were performed using
SPSS 17.0 software (SPSS Inc. Chicago, IL, USA). A p-
value of < 0.05 was considered statistically significant.
Results
Validation of PAH animal model
The experimental timeline is shown in Fig. 1. First, we
validated the MCT-induced PAH model, the most com-
mon experimental model for PAH in rats [23]. Pulmon-
ary hypertension was indicated by a significant increase
in RV systolic pressure (RVSP) compared with the con-
trol rats (Additional file 1: Figure S1A, p < 0.05). Pro-
gressive increases in RV/ (LV + S) (Additional file 1:
Figure S1B) were also observed. These changes were as-
sociated with muscularization and wall thickening of the
pulmonary arterioles (Additional file 1: Figure S1C–H).
Moreover, pneumonectomized rats that received MCT
not only consistently demonstrate neointimal formation
(Additional file 1: Figure S2C-H), but also higher RVSP
(Additional file 1: Figure S2A) and higher RV/ (LV + S)
(Additional file 1: Figure S2B). High death rates were ob-
served among the PAH rats at 4 weeks after MCT injec-
tion; however, no control rats died during the
experimental period. In the present study, we used the
two model to investigate the expression of CF6 in MCT-
induced PAH.
CF6 expression in PAH rats
We first measured the CF6 mRNA level in lung tissue
and the circulation in both MCT induced and MCT plus
pneumonectomy induced PAH. We found that under
physiological conditions, the CF6 mRNA level was low
in the lung tissue. However, a 2-6-fold increase was ob-
served in the lungs of the MCT-injected rats in a time-
dependent manner, starting at 1 w, peaking at 3w and
remaining high at 4 w after MCT injection relative to
the levels in the sham group (Fig. 2h, p < 0.01). Mean-
while, the circulating CF6 level did not increase until 2
w after MCT injection, and it remained high at 4 w
(Fig. 2g). We further reveal the expression profile in
MCT plus left pneumonectomy in which the pattern of
vascular remodeling resembles the neointimal lesions
seen in PAH, to address the problem of determining
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whether CF6 expression is alerted. As a result, CF6 gene
expression and plasma concentration in pneumonecto-
mized MCT- injected rats increased in a similar manner
to a higher level than in MCT injected rats (Fig. 2i, j),
while the circulating CF6 level increased earlier at 1 w
after MCT injection, and it remained high at 4 w
(Fig. 2i). To determine CF6 expression in the lung, tissue
sections were immunostained for CF6. Immunohisto-
chemistry (IHC) analysis revealed a small quantity of
CF6-positive endothelial cells in the pulmonary vascula-
ture (Fig. 2a, d), in consistent with previous findings in-
dicating that CF6 is present on the surface of human
vascular endothelial cells. However, in the MCT-injected
rats and pneumonectomized MCT- injected rats, intense
immunostaining revealed that CF6 was released outside
of ECs and spread throughout the arteries and in local
tissues in a paracrine manner (Fig. 2b, c, e, f ). Given its
marked regulation in the PAH rats lung [24], we next
sought to examine the expression of CF6 in lung speci-
mens from patients with lung cancer. CF6 was consider-
ably expressed in pulmonary arteries and lung tissues
from patients with NSCLC, but was limited expressed in
ECs and barely detectable in normal lung tissue (Add-
itional file 1: Figure S3), suggesting that CF6 might be
both an obvious marker of impaired endothelium and a
novel risk factor contributing to vascular damage. The
elevation of CF6 in MCT-induced PAH led us to
hypothesize that CF6 might be an initiating factor for
PAH, and that blocking CF6 peptide using recombinant
AAV-2 carrying the rat CF6 short hairpin small-
interfering RNA could prevent development of PAH.
Intratracheal delivery and AAV2-mediated CF6 knock-
down in vivo
As is shown in Fig. 3a, fluorescence microscopic detec-
tion of GFP expression in lungs of experimental animals
was used to evaluate the distribution of delivered shRNA
or control virus. Our results showed that the GFP was
expressed in lung tissues, indicating that the shRNA
complex could be efficiently delivered to lungs in vivo
via intratracheal injection (Fig. 3a). RT-PCR and West-
ern blotting were performed to further confirm the
knockdown efficiency of CF6 shRNA (Fig. 3b, c). As a
result, mRNA and protein levels were clearly lower, in
Fig. 1 Timeline of the experiment and schematic diagram for (A) CF6 expression study. (B) CF6 knockdown study: (a) sham and MCT-vehicle
group; (b) MCT-shRNA group and MCT-control group for prevention study; (c) MCT-shRNA group and MCT-control group for reversal study
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the CF6 shRNA-MCT group compared with the corre-
sponding MCT-control group (p < 0.01), while similar to
that observed in the normal rats, indicating that CF6 ex-
pression was effectively eliminated. Though as a vaso-
constrictor, CF6 RNA silencing delivered intratracheally
did not affect systemic blood pressure (Table 1). These
data suggest that one single-injection of specific shRNA
achieved high efficacy for continuous and stable selective
deletion of CF6 for at least 4 weeks.
AAV2-mediated CF6 knockdown reduced pulmonary
vascular remodeling
PAH causes pulmonary vascular remodeling [15]. There-
fore, we evaluated remodeling by measuring wall
thickness of the pulmonary arterioles. As shown in Fig. 4,
in vessels with diameters ranging from 50 to 100 μm,
wall thickness was significantly increased from 63.5 ±
2.1 % (sham group) to 80.2 ± 4.3 % and 79.5 ± 4.56 %
(MCT-control groups). Pretreatment with AAV2-CF6-
shRNA reduced the IPA wall thickness to 70.3 ± 2.5 %
(p < 0.05 vs. MCT-control; Fig. 4). Meanwhile, no signifi-
cant difference in this parameter was found between the
MCT-vehicle and MCT-control groups (data not
shown). Similar results were observed in vessels with di-
ameters of less than 50 μm. Accordingly, PCNA expres-
sion in PASMCs was higher in the control-MCT group
compared with the sham group, and CF6 RNAi dimin-
ished this increase (p < 0.05). The downregulated α-SMA
Fig. 2 a-f IHC staining of CF6 in the sham group (a, d), MCT-vehicle group (b, c) and MCT plus left pneumonectomy group (e, f) at 4 w after MCT
injection. Quantification of serum CF6 levels at 1 w, 2 w, 3 w, 4 w by ELISA in MCT-vehicle group (g) and MCT plus left pneumonectomy model (i). Relative
CF6 mRNA levels in MCT-vehicle group (h) and MCT plus left pneumonectomy model (j), as detected by quantitative RT-PCR. The results are expressed as
the mean ± SD. Bar = 30 μm. **p< 0.01 and *p< 0.05. IHC, immunohistochemistry; MCT, monocrotaline; PAH, pulmonary artery hypertension;
P, pneumonectomy
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Fig. 3 Transduction efficiency after intratracheal injection of CF6 shRNA in vivo. Representative image of GFP expression (a) in lung tissues of rats
at 2w after CF6 shRNA or GFP vector injection in sham group, control vector group and CF6 shRNA group (n = 4 for each group). Cell nuclei were
labeled with DAPI DNA stain (blue). Bar = 50 μm. b, c CF6 (18 KDa) protein levels normalized by GAPDH (36 KDa), as analyzed by Western blot
and relative CF6 mRNA levels, as detected by quantitative RT-PCR in the sham, vehicle, −2w-MCT, −2w-shRNA, 2w-MCT and 2w-shRNA
groups. **p < 0.01.
Table 1 Hemodynamics and echocardiography data at 28 day after MCT injection
Parameters Sham Vehicle −2w-MCT −2w-shRNA 2w-MCT 2w-shRNA
No. of surviving rats 20 19 18 18 17 16
Body weight, g 360 ± 8 296 ± 5* 291 ± 6* 335 ± 7*,** 286 ± 7* 323 ± 6*,**
Heart Rate, bpm 418 ± 12 420 ± 16 425 ± 14 422 ± 15 428 ± 16 426 ± 15
Cardiac Output (ml/min) 134 ± 2.3 107 ± 4* 107 ± 4* 116 ± 3.4* 109 ± 4.2* 112 ± 2.8*
Ejection Fraction (%) 66.8 ± 4.2 48.7 ± 4.6* 46.8 ± 3.9* 67.2 ± 5.3** 47.6 ± 4.3* 64.5 ± 3.4**
Pulmonary artery , cm 0.295 ± 0.01 0.41 ± 0.025* 0.38 ± 0.03* 0.317 ± 0.03** 0.42 ± 0.04* 0.336 ± 0.02**
Mean blood pressure 92.5 ± 3.2 88.5 ± 4.7 89.6 ± 3 90.8 ± 2.5 87.4 ± 3.2 88.3 ± 3.6
RV/BW (mg/g) 3.7 ± 0.2 10 ± 0.9* 9.7 ± 1* 5.6 ± 0.8*,** 9.4 ± 0.9* 6.2 ± 0.7*,**
RV wall thickness, cm 0.12 ± 0.01 0.21 ± 0.03* 0.21 ± 0.04* 0.13 ± 0.03** 0.22 ± 0.03* 0.16 ± 0.02**
RV area, mm2 11.7 ± 0.3 22 ± 0.7* 21.5 ± 0.6* 12.5 ± 0.5** 21 ± 0.4* 14.6 ± 0.4*,**
LV area, mm2 22.1 ± 0.4 22.5 ± 0.5 22.4 ± 0.4 22.3 ± 0.7 22.6 ± 0.5 22.4 ± 0.6
RV right ventricle, LV left ventricle, BW body weight. All values are mean ± SD
*p <0.05 compared with sham group
**p < 0.05 compared with respective control MCT group
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Fig. 4 Effect of AAV-CF6 shRNA on pulmonary vascular remodeling. a Hematoxylin and eosin and IHC staining of (b) alpha-actin with an α-SMA antibody,
(c) of macrophages with a CD68 antibody, and (d) of vascular proliferation of lung tissues with a PCNA antibody in the (a) sham, (b) -2w-MCT, (c) -2w-
shRNA, (d) 2w-MCT and (e) 2w-shRNA groups, respectively. e Ratios of vascular medial thickness (i.e., smooth muscle thickness) to the outer diameter (total
vessel wall thickness) of the small pulmonary arteries in the PAH and normal rats. f Numbers of CD68-positive macrophage cells per 20 high-power fields
(HPFs). g Relative changes in the number of PCNA-positive cells in pulmonary arterial walls, which were significantly different from the number in the
MCT-control group. **p< 0.01, *p< 0.05 compared with sham; †p< 0.05 compared with -2w-MCT; #p< 0.05 compared with -2w-shRNA; and @ p< 0.05
compared with 2w-MCT
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and PCNA expression and reduced intrapulmonary pul-
monary artery (IPA) medial wall thickness by CF6
shRNA, implicated that MCT caused decreased severity
of pulmonary vascular muscularization, reversed pro-
gression of pulmonary vascular remodeling. In addition,
densitometric quantification of CD68 protein indicated
significantly reduced macrophage infiltration both by
treatment and pretreatment with CF6 shRNA (Fig. 4g).
These results indicate that CF6 upregulation is involved
in MCT-induced pulmonary vascular remodeling.
AAV2-mediated CF6 knockdown ameliorated pulmonary
hypertension
We then analyzed the hemodynamic data and echo-
cardiographic changes at 4 w to determine whether
CF6 silencing affects right ventricular pressure and
right heart hypertrophy. As a result, RVSP was
found to be attenuated in the rats pretreated with
CF6 shRNA (33.6 ± 2.9 mmHg, p < 0.05 vs. the MCT
group) (Fig. 5a, b). Similarly, CF6 shRNA administra-
tion reduced the increases in the RV/ (LV + S) ratio
(p < 0.05; Fig. 5c) and the RV/BW (p < 0.05; Table 1).
Administration of CF6 RNAi 2 weeks after MCT in-
jection completely inhibited the progression of PAH
and RV dysregulation as well. No significant differ-
ences were found between the two control-MCT
groups. These findings indicate that the enhanced
CF6 plays an important role in the pathogenesis of
MCT-induced PAH and RV dysfunction, and provide
a potential therapeutic target.
As shown in Table 1, the rats that received the CF6
shRNA treatment prior to or after MCT administration
showed significant reductions in RV wall thickness, RV
area, and pulmonary artery diameter compared with the
MCT-induced rats; the CO level was slightly but not
significantly increased in these animals relative to the
controls (p > 0.05) due to enhanced stroke volume,
but the heart rate was not altered. Furthermore, the
LV area in the MCT-injected rats did not signifi-
cantly change compared with the sham rats. In
addition, low death rate was observed in the CF6
shRNA-treated PAH rats. These findings demonstrate
that inhibition of CF6 decreases RVSP and RVHI.
Our data also demonstrated that treatment with CF6
shRNA improved survival assessed at day 28 com-
pared with MCT alone compared with those trans-
fected with control vector alone both in
pretreatment and treatment manner (log rank test p
< 0.05; Additional file 1: Figure S4A, B). No definite
adverse effects were detected after transfer of CF6
shRNA.
Delivery of CF6 shRNA reversed endothelial dysfunction
of pulmonary artery rings in MCT-induced PAH
Following completion of the treatment, the pulmonary ar-
tery rings were removed from the rats and prepared for
isometric tension recording to evaluate endothelial
dysfunction. The vasodilator responses of the pulmonary
artery rings to increasing concentrations of ACh were
reduced in the rats that received MCT. The maximum
relaxation induced by ACh was reduced from 55.6 ± 5.1 %
(sham) to 31.5 ± 3.0 % and 28.6 ± 3.9 % (MCT-vehicle) (p
< 0.05 vs. sham). These results indicate that MCT admin-
istration induces endothelial dysfunction of the pulmonary
artery rings. Intratracheal injection of shRNA CF6 before
or after MCT injection restored the maximal relaxation
induced by ACh to 50.9 ± 4.5 % and 45.8 ± 6.4 % (p < 0.05
vs. MCT-control, Fig. 6), suggesting that CF6 inhibition
exerts its beneficial effect by reducing endothelial dysfunc-
tion of the pulmonary artery rings in PAH rats.
Fig. 5 Targeted CF6 silencing alleviates hemodynamic changes and right ventricular hypertrophy in PAH rats at 4 weeks after MCT exposure. a
Representative hemodynamic data (RVSP) obtained with a Labchart acquisition system. b CF6 shRNA decreased RVSP in the MCT-control group. c CF6
shRNA also reduced the RV/LV + S ratio in the MCT-treated rats. The data represent the mean ± SD. **p < 0.01 and *p < 0.05. RVSP, right ventricle
systolic pressure; RV/LV + S ratio, weight ratio of the right ventricle to the left ventricle plus the septum
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Effects of endogenous CF6 on prostacyclin production in
lung tissues and serum
PGI2 plays an important role as an endogenous regu-
lator of vascular homeostasis, inhibiting platelet ag-
gregation and VSMC proliferation and migration [25].
6-keto-PGF1a, a stable metabolite of prostacyclin,
were analyzed to assess prostacyclin production. As il-
lustrated in Fig. 7, the 6-keto-PGF1a production rates
at baseline were 175 ± 61 pg/μg and 838 ± 174 pg/ml
in lung tissues and serum samples, respectively. MCT
injection significantly decreased these rates (both p <
0.05), which is negatively correlated with the in-
creased CF6 level. Meanwhile, knockdown of CF6
peptide prevented the MCT induced increase in CF6
and reversed 6-keto-PGF1a production in both the
lung tissues (58 ± 24.8 vs. 115 ± 43 pg/μg, p < 0.05 and
60 ± 26.8 vs. 91.6 ± 32.9 pg/μg, p < 0.05, respectively)
and serum samples (180.3 ± 54 vs. 580.6 ± 130.3 pg/
ml, p < 0.05 and 180.3 ± 54.4 vs. 541.7 ± 111.3 pg/ml,
p < 0.05, respectively) compared with the MCT-
control group. No significant differences were found
between the two MCT-control groups. This suggests
that the enhanced CF6 may function via inhibition of
prostacyclin generation in the progression of PAH.
Discussion
To our knowledge, the current study is the first to eluci-
date the role of CF6 in the pathology of PAH. A single
injection of MCT caused persistent severe PAH, which
shares important features with human diseases, such as
pulmonary arterial endothelial cell (EC) injury and sub-
sequent pulmonary artery smooth muscle cell (PASMC)
hypertrophy [26]. Based on the model, we demonstrated
that (1) CF6 was significantly upregulated in lungs and
serum of PAH rats, specifically, in the lung tissues; (2)
CF6 gene silencing using AAV2-CF6-shRNA induced
down-regulation of CF6 protein in the lung tissues of
the PAH rats, along with reversed prostacyclin synthesis;
and (3) transfer of CF6 shRNA ameliorated MCT-
induced pulmonary vascular remodeling and PAH pro-
gression. Finally, we demonstrated that (4) CF6 knock-
down as a therapeutic approach in the MCT rats
without causing definite adverse effects.
CF6, a component of the peripheral stalk in ATP syn-
thase under physiological conditions, is known to elicit
its novel function outside the cells after being released
from the plasma-membrane of ATP synthase in a patho-
logical state [27]. In clinical settings, we and others have
previously shown that the plasma CF6 level increases in
Fig. 6 Acetylcholine (ACh)-induced relaxation of pulmonary artery rings from the sham, −2 w-MCT, 2 w-MCT, −2 w shRNA and 2 w shRNA rats. The
data are presented as the mean ± SD. **p < 0.01 compared with the sham group; † p < 0.05 compared with the −2 w-MCT group; and # p < 0.05
compared with the 2 w-MCT group. All groups were evaluated at 28 days after MCT injection
Fig. 7 Levels of 6-keto-PGF1a in lung tissue (a) and plasma (b). The results are expressed as the mean ± SD. **p < 0.01
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various cardiovascular disorders, where a cause–result
connection between increased plasma CF6 and de-
creased PGI2 has been indicated [8, 28–30]. However,
the CF6 level in PAH has not been explored. There ex-
hibited significant overproduction of CF6 in the lung tis-
sues and elevation in circulating CF6 among PAH rats of
MCT models and MCT plus pneumonectomy models,
most likely due to mechanical stress secondary to the el-
evated pulmonary pressure and the inflammation activa-
tion induced by MCT, such as NF-kB activation and
TNF-α releasing [7, 31, 32]. ECs represents a main
source of circulating CF6 [9]. In hypertension study,
intravenous injection of recombinant CF6 mimetics in-
creased blood pressure transiently, apparently by sup-
pressing PGI2 synthesis, whereas a specific antibody
against CF6 decreased systemic blood pressure with a
concomitant increase in plasma PGI2 in hypertension
rats. Except for endocrine manner, our data showed that
the limited distributed CF6 observed in ECs in normal
rats was released into surrounding tissues and may inter-
act with the interact with plasma membrane ATP syn-
thase, the receptor of CF6 presented on vascular cells
such as ECs and vascular smooth muscle cells (VSMCs)
function in a paracrine manner, supported by a previous
study identified that the high local CF6 levels in tissues
such as resistance arterioles could directly enhancing
Ca2+ signaling in VSMCs and vasoconstriction in the
mesenteric arteriolar network in a paracrine manner
[10]. In addition, the CF6 level did not affect systematic
blood pressure in PAH rats. Therefore, it appears that
different from the direct role in pathological hyperten-
sive as a systemic hormone and vasoconstrictor, CF6
may function on PAECs and PASMCs in a paracrine
manner in PAH, which is consistent with the fact that
pulmonary circulation is selectively inhibited in humans
with PAH.
We chose the RNAi strategy over CF6 antibodies to
further determine whether the high CF6 level is a cause
or merely an effect of PAH given that a therapeutic anti-
body should decrease the circulating levels of free CF6
to zero and have a limited duration of effect [33], and es-
pecially considering that CF6 signaling proteins have
short half-lives. Various “RNA interference (RNAi) ther-
apeutics” have already entered clinic trials [34]. Investi-
gators showed that AAV-2 is an efficient vector for
delivering genes to pulmonary vessels and lungs to treat
PAH [35]. We adopted the intratracheal route for AAV2
delivery of CF6 shRNA because the majority of drugs
targeting the vasculature will, if administered systemic-
ally, affect normal circulation as well; in contrast, gene
transfer of specific peptides to bronchial epithelial cells
and alveolar cells selectively affects the pulmonary artery
in animal models [36, 37]. As a result, CF6 RNAi re-
versed ECs dysfunction and PA remodeling, indicating
that through the secretion of CF6, ECs regulates the pro-
liferation of SMCs in their vicinity. The data described
above revealed that, in addition to its vasoconstrictive
properties, CF6 is also involved in the proliferation of
PASMCs. The downstream signaling of CF6 is mediated
via plasma membrane ATP synthase receptor. After
combination, the molecular rotary motor, F1-ATPase in
ECs and VSMCs, forcefully hydrolyzes ATP in a mode
that is in the reverse direction of the mode used in the
mitochondria. Then, this hydrolysis inversely rotates the
Fo motor against the original clockwise direction, result-
ing in proton import. CF6 and the plasma membrane-
F1Fo complex mediated VSMC remodeling is well estab-
lished and that the downstream the intracellular pH
(pHi) changes are associated with cell proliferation and
migration in VSMCs [28]. Additional methods of CF6
intervening in vitro are needed to define the underlying
post receptor signaling mechanisms and the direct role
of CF6 on ECs and PASMCs.
Suppressed PGI2 is a well-known target of the increasing
intracellular acidosis of CF6. In PAH, the primary effects of
IP receptor activation (e.g. by prostacyclin or its analogues)
are the induction of pulmonary artery dilation and the in-
hibition of vascular smooth muscle cell proliferation. Treat-
ments that target the prostacyclin pathway are crucial for
the effective management of patients with PAH [25, 28, 38,
39]. Our results indicated that the impaired PGI2 gener-
ation was enhanced in PAH by the overproduction of CF6
and restored by CF6 silencing. Therefore, we speculate that
the impaired pulmonary vascular PGI2 generation may be
the target of CF6 and contributes to pulmonary vasocon-
striction and the excessive medial hypertrophy observed in
this PAH model. In addition, the CF6 peptide may influ-
ence PAH by a more direct mechanism that may be inde-
pendent of the complex effects of PGI2. After binding to
the β-subunit of the ATP synthase at the cell surface, CF6
could further activate c-Src or RAC1 [7, 10, 40], which po-
tentially enhances Ca2+ influx and sensitization [10, 28, 41,
42]. Aberrant expression of these downstream signaling
proteins cause a mitochondrial metabolic abnormality that
plays a pathophysiological role in PAH. Moreover, RNAi of
CF6 effectively prevented macrophage infiltration, which is
involved in the development of PAH-associated vascular le-
sions and has been well documented in humans [43, 44].
This suggests that CF6 plays a critical role in the inflamma-
tion process of PAH; however, the complex mechanism
remains poorly understood. These theories provide a strong
impetus for ongoing efforts to define the mechanisms of
CF6.
Prospective
Although many vasodilators have antiproliferative effects
on VSMCs, there is no definitive evidence that pulmonary
vascular remodeling in human PH is reversible. Therefore,
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novel approaches that directly target pulmonary vessel
wall pathology are needed to reverse the established pul-
monary vascular pathology in PH patients. We found that
CF6 levels increased in MCT model, MCT plus left pneu-
monectomy model and human lung cancer tissue, while
the AAV2-based RNAi targeting CF6 reversed the PA re-
modeling and PH in MCT-induced PAH. The above
makes CF6 a target molecule for novel therapeutic strat-
egies in the treatment of clinical PH regardless of the dif-
ferent clinical forms. Future experiments on
hypertrophied pulmonary arterioles and lung tissues from
human samples with PAH are needed to confirm CF6 ex-
pression. Besides, despite of the fact that CF6 is implicated
in multiple clinical settings and experimental models, no
pharmacologically active small molecule inhibitors of CF6
has been developed. Therefore, the specific plans aiming
at blocking CF6 pathway that can be applied in PAH treat-
ment is warranted to be explored in the future.
Limitations
First, the MCT-induced PAH model does not accurately re-
flect the clinical picture of PAH in humans and the high
death rate could cause potential selective bias. Further in-
vestigations of other animal models of PAH (Sugen-hyp-
oxia) are needed to determine the clinical efficacy of CF6
inhibition. Second, our study was performed within a lim-
ited window of time and involved only short-term animal
research; therefore, the results only provide an impetus for
further clinical investigation. Third, the AAV vectors used
were capable of inserting their genome at random positions
in the host chromosomes, which eventually restricts gene
function and may cause mutations. Moreover, the interpret-
ation of RNAi data is complicated by unintended interac-
tions between silencing molecules and cellular
components, and additional shRNA sequences should be
designed to decrease the risk of unwanted artifactual off-
target effects [45]. Despite these limitations, our data dem-
onstrate a potential role of airway delivery of shRNA-CF6
in paracrine inhibition of CF6 secretion into the pulmonary
vasculature in PAH human clinical trials.
Conclusions
Our results demonstrate that CF6 is activated during
pathogenesis of PAH. Additionally, targeted CF6 silen-
cing diminishes the MCT-mediated induction of PAH
with down-regulation of PGI2, decrease in RVSP, re-
versal of pulmonary arterial remodeling, and im-
proved RV dysfunction. Therefore, CF6 holds a
promise therapeutic target for PAH. Our study was
time-limited as a short term animal research, and the
results only provided us an impetus for further clin-
ical investigations.
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